A first-in-human, randomized, double-blind, placebo-controlled, single-ascending dose (healthy volunteers and CHD [coronary heart disease] patients) and multiple dose (CHD patients) study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of APL180.

Trial Profile

A first-in-human, randomized, double-blind, placebo-controlled, single-ascending dose (healthy volunteers and CHD [coronary heart disease] patients) and multiple dose (CHD patients) study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of APL180.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Sep 2012

At a glance

  • Drugs APL 180 (Primary)
  • Indications Coronary disorders
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 09 Oct 2009 Actual end date (Sep 2009) and actual number of patients (176) added as reported by ClinicalTrials.gov.
    • 09 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Jun 2008 The expected completion date for this trial has been extended from Mar 2008 to Dec 2008 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top